Targeting RNAs to diminish the epigenetic ravages of aged skin – Webinar Wednesday 25 January
Winner of the IFSCC 2022 London Congress Best poster Award, Dr Paul Lawrence (Executive Director of Research and Discovery, Biocogent) will share his work on using microRNAs to increase skin fiber proteins and counter wrinkle formation in our webinar, Targeting Small Non-coding RNAs to Diminish the Epigenetic Ravages of Aged Skin, on 25 January at 11h NYC time.
Highlights will include:
- Introduction to the application of small non-coding RNA molecule effectors of RNA interference (RNAi) – specifically microRNAs – to improve skin features
- MicroRNA profiling experiments demonstrating how topical products can impact the levels of various microRNAs in the skin
- Laboratory illustration of the impact of using microRNA ‘mimic’ molecules to affect a skin brightening effect in melanocyte-derived cells using a proprietary delivery vehicle
- Demonstration of impact of topical application of microRNA ‘mimics’ to brighten skin in a three-dimensional skin model system using a proprietary delivery vehicle
- Efficacy of an anti-microRNA – ‘antagomiR’ – to circumvent endogenous microRNAs to affect an increase in skin fiber proteins and counter wrinkle formation
Times West Coast USA 8h • Mexico City / Chicago 10h • Bogota / East Coast USA 11h • Sao Paolo 13h • UK 16h • Central Europe 17h • J’burg / Tel Aviv 18h • New Delhi 21h30 • Sing / HK / China / Taipei 0h • Japan / Korea 1h Thursday • Melbourne 3h Thursday • Wellington 5h
Dr Paul Lawrence received his doctorate in molecular microbiology from Stony Brook University and before that obtained his Bachelor of Science degree in molecular biology from the University of New Mexico. During his career, he has conducted biological research in academia, industry and for the US government. He has executed anti-viral therapeutic and vaccine research at Brookhaven National Laboratory and the Plum Island Animal Disease Center. In industry, he has participated in contract biopharmaceutical projects for the former Collaborative Bioalliance and Dow Chemical. Dr Lawrence was also the Director of DNA Production for the anti-counterfeiting biotechnology company, Applied DNA Sciences. He is currently Executive Director of Research and Discovery for Biocogent. In his scarce spare time he is also an adjunct professor teaching microbiology to future nurses and doctors. Over the course of his career, Dr Lawrence has published more than 30 research manuscripts and review articles, more than 25 online science digests, and has authored a textbook chapter on the molecular pathogenesis of one of the world’s most infectious viruses.